Radioimmunoimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigen
Radioimmunolocalization of an /sup 111/In-labeled, mouse antimelanoma monoclonal antibody (MAb), ZME-018, was examined in 30 patients with metastatic malignant melanoma. Each patient received a single iv infusion of MAb at concentrations ranging from 0.6 to 40 mg, coupled to 5 mCi /sup 111/In by the chelating agent pentetic acid. No toxicity was observed in any patient. Total-body and region of interest scans performed at 4, 24, and 72 hours following MAb administration revealed uptake in 110 of 171 previously diagnosed metastases for a sensitivity of 64%. Nonspecific uptake of radioactivity was consistently observed in the liver and spleen, and less frequently in the bowel, testes, axillae, and bone. Sensitivity of detection increased significantly at doses of MAb above 2.5 mg, with 74% of the lesions imaging at 20 mg/5 mCi compared with 29% at 2.5 mg/5 mCi (P less than .005). Sensitivity actually decreased slightly at the 40-mg dose. There was a significant correlation between tumor uptake of MAb-/sup 111/In-conjugate and increasing tumor size. Soft tissue lesions, such as skin and lymph node metastases, were imaged to a greater extent (77%) than were visceral metastases (40%). Mean plasma clearance of ZME-018 was prolonged with a half-life of 33.6 hours in patients receiving 40 mg, compared with 17.8 hours in patients given 2.5 mg (P less than .01). Urinary excretion of the isotope averaged 11.4% of the injected dose over 48 hours. Hence radioimmunolocalization of melanoma with /sup 111/In-ZME-018 appeared feasible. The sensitivity of the technique varies with MAb dose, specific activity of /sup 111/In-MAb conjugate, tumor size, and disease site.
- Research Organization:
- Univ. of Texas System Cancer Center, Houston
- OSTI ID:
- 6523809
- Journal Information:
- NCI Monogr.; (United States), Vol. 3
- Country of Publication:
- United States
- Language:
- English
Similar Records
Imaging findings and pharmacokinetics of 111-indium ZME-018 monoclonal antibody (MoAb) in malignant melanoma
Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018)
Related Subjects
BODY
RADIOISOTOPE SCANNING
METASTASES
DIAGNOSIS
MONOCLONAL ANTIBODIES
DIAGNOSTIC USES
LABELLING
BIOLOGICAL HALF-LIFE
BIOLOGICAL LOCALIZATION
BLOOD-PLASMA CLEARANCE
INDIUM 111
MELANOMAS
MOLECULAR WEIGHT
PATIENTS
SENSITIVITY ANALYSIS
UPTAKE
ANTIBODIES
BETA DECAY RADIOISOTOPES
CLEARANCE
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
INDIUM ISOTOPES
INTERMEDIATE MASS NUCLEI
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
MINUTES LIVING RADIOISOTOPES
NEOPLASMS
NUCLEI
ODD-EVEN NUCLEI
RADIOISOTOPES
USES
550601* - Medicine- Unsealed Radionuclides in Diagnostics